Japanese Journal of Cancer and Chemotherapy最新文献_第6页

[A Case of Pulmonary Epithelioid Hemangioendothelioma Associated with Multiple Cancers]. 【肺上皮样血管内皮瘤合并多发性肿瘤1例】。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-05-01

Kanetaka Maeshiro, Yoshiki Chinen, Kouji Yoshikawa, Jun Miyagi

引用次数: 0

[Preventive Effect of Saline Eye Wash for Eye Symptoms Due to High-Dose and Intermediate-Dose Cytarabine Therapy]. [盐水洗眼对高、中剂量阿糖胞苷治疗引起的眼部症状的预防作用]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-05-01

Yasutaka Sumi, Yuki Yasutaka, Kentaro Ogata, Keisuke Sato, Masahiro Okurano, Motoyasu Miyazaki, Shota Hagio, Yuta Nakashima, Yasushi Takamatsu, Osamu Imakyure, Hidetoshi Kamimura

{"title":"[Preventive Effect of Saline Eye Wash for Eye Symptoms Due to High-Dose and Intermediate-Dose Cytarabine Therapy].","authors":"Yasutaka Sumi, Yuki Yasutaka, Kentaro Ogata, Keisuke Sato, Masahiro Okurano, Motoyasu Miyazaki, Shota Hagio, Yuta Nakashima, Yasushi Takamatsu, Osamu Imakyure, Hidetoshi Kamimura","doi":"","DOIUrl":"","url":null,"abstract":"Background: Hematologic malignancies have shown improved prognosis in some diseases owing to advanced treatment. Cytarabine (Ara-C) is widely used for treatment; however, ocular symptoms frequently occur as a side effect. In this retrospective study, we investigated the preventive effect of combining corticosteroid eye drops with saline eye wash on ocular symptoms in patients receiving high-dose or intermediate-dose Ara-C therapy without concomitant radiation therapy.Methods: Patients with hematologic malignancies who received high-dose or intermediate-dose Ara-C therapy at Fukuoka University Hospital between January 2010 and April 2020 were included in this study. The incidence of ocular symptoms was evaluated, using the Kaplan-Meier method, to compare patients with and without saline eye wash in the high-dose and intermediate-dose Ara-C groups.Results: The incidence of ocular symptoms was 18.4% (9/49) and 8.2% (4/49) in the high-dose and intermediate-dose groups, respectively. There was no significant difference between the saline eye wash group and the nonwash group. Ocular symptoms improved with observation or adjustment/continuation of the eye drop treatment.Conclusions: In high-dose and intermediate-dose Ara-C therapy without concomitant radiation, corticosteroid eye drops alone were effective in preventing ocular symptoms, suggesting that combination with saline eye wash may not necessarily be beneficial.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 5","pages":"347-351"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148158433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Somatic Mosaicism and Clonal Evolution]. 体细胞镶嵌和克隆进化。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-05-01

Nobuyuki Kakiuchi

引用次数: 0

[Long-Term Survival in Three Cases with Pulmonary Metastases from Colorectal Cancer Given Low-Dose S-1 Under a Regimen Combining a Carbohydrate-Restricted Ketogenic Diet, Metformin, Vitamin D, Eicosapentaenoic Acid, and Other Complementary Therapies]. [3例结直肠癌肺转移患者低剂量S-1联合限制碳水化合物生酮饮食、二甲双胍、维生素D、二十碳五烯酸和其他补充治疗方案的长期生存率]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-05-01

Fumio Yamazaki, Yoshiyuki Saegusa, Munemitsu Kobayashi, Naoki Murata, Tomoyuki Moriya, Masaru Miyazaki

{"title":"[Long-Term Survival in Three Cases with Pulmonary Metastases from Colorectal Cancer Given Low-Dose S-1 Under a Regimen Combining a Carbohydrate-Restricted Ketogenic Diet, Metformin, Vitamin D, Eicosapentaenoic Acid, and Other Complementary Therapies].","authors":"Fumio Yamazaki, Yoshiyuki Saegusa, Munemitsu Kobayashi, Naoki Murata, Tomoyuki Moriya, Masaru Miyazaki","doi":"","DOIUrl":"","url":null,"abstract":"Chemotherapy is the standard treatment for patients with stage Ⅳ colorectal cancer. However, some patients are unable to continue standard chemotherapy because of adverse side effects, while others decline this treatment option to maintain a higher quality of life (QOL). To address the parallel needs for high QOL and disease control, we developed an alternative therapeutic approach termed\"Coexistence Therapy for Cancer,\"employing the combination of a carbohydrate-restricted ketogenic diet, metformin, vitamin-D, eicosapentaenoic acid (EPA) and additional complementary therapies, with S-1 (tegafur/gimeracil/oteracil potassium) at doses low enough to avoid side effects. Carbohydrate-restricted ketogenic diets, drugs, and other complementary therapies affect cancer cell metabolism, thereby limiting the growth of cancer cells and impairing their survival. An investigator-initiated clinical trial was conducted to evaluate the efficacy and safety of this approach. We assessed changes in the tumor size of the target lesions, serum carcinoembryonic antigen levels, and QOL. Our 3 patients with postoperative colorectal cancer with pulmonary metastases achieved long-term survival while maintaining a favorable QOL. These findings suggest that this therapeutic strategy may serve as a complementary treatment option for patients who are unable to tolerate standard chemotherapy. Further accumulation of clinical cases is required to validate the effectiveness of this approach.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 5","pages":"352-356"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148158442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[A Case of Unresectable Colon Cancer Treated with Pembrolizumab That Underwent Conversion Surgery]. 【用派姆单抗治疗不可切除结肠癌并行转化手术1例】。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-04-01

Shinichiro Chino, Hiroyuki Egi, Ryo Ota, Toshimasa Fujio, Masahiro Maruyama, Motohiro Chuman, Yasushi Kondo, Takashi Kaizu, Yasuto Kondo, Takeshi Naito

引用次数: 0

[A Case Report of Robot-Assisted Laparoscopic Distal Gastrectomy for Gastric Cancer with Concurrent Malignant Lymphoma]. [机器人辅助腹腔镜胃远端切除术治疗胃癌并发恶性淋巴瘤1例报告]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-04-01

Junji Kawada, Daichi Tanaka, Ken Nakamura, Satoshi Eguchi, Yoshiki Taniguchi, Hiromitsu Hoshino, Shinya Yamashita, Shigeyuki Tamura, Hitoshi Mizuno

{"title":"[A Case Report of Robot-Assisted Laparoscopic Distal Gastrectomy for Gastric Cancer with Concurrent Malignant Lymphoma].","authors":"Junji Kawada, Daichi Tanaka, Ken Nakamura, Satoshi Eguchi, Yoshiki Taniguchi, Hiromitsu Hoshino, Shinya Yamashita, Shigeyuki Tamura, Hitoshi Mizuno","doi":"","DOIUrl":"","url":null,"abstract":"The patient was a woman in her 70s. Screening endoscopy revealed a 0-Ⅱc lesion on the lesser curvature of the gastric antrum, and biopsy confirmed a well-differentiated tubular adenocarcinoma (tub1). Endoscopic submucosal dissection (ESD) was performed; however, pathological findings indicated non-curative resection (eCura C-2). She was referred to our department for additional surgical treatment. Preoperative computed tomography showed mild enlargement of mesenteric lymph nodes, with no enlargement of regional lymph nodes. A robot-assisted laparoscopic distal gastrectomy with D2 lymph node dissection was planned using the Da Vinci X system. Intraoperatively, clustered small lymph nodes were noted at station #6. One was excised and submitted for intraoperative rapid diagnosis, which revealed no evidence of metastasis. Based on this result, D2 dissection was carried out as planned. The operation was completed without complications, and the patient was discharged on postoperative day 8. Histopathological examination revealed no residual gastric carcinoma or lymph node metastasis; however, immunohistochemical analysis of the lymph nodes revealed features consistent with follicular lymphoma (Grade 1). As the patient had no systemic symptoms or high tumor burden, a watch-and-wait strategy was adopted. This case highlights the utility of robot-assisted surgery in safely excising enlarged lymph nodes and guiding the extent of lymphadenectomy.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 4","pages":"302-304"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148017764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[A Case of Locally Advanced Colorectal Cancer with Severe Bladder Invasion Successfully Treated with Preoperative Chemotherapy with Anti-EGFR Antibody and Avoiding Total Bladder Resection]. 【局部晚期结直肠癌伴严重膀胱侵犯术前抗egfr抗体化疗避免全膀胱切除成功1例】。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-04-01

Jyunta Hayashi, Kiichi Sugimoto, Saki Kochi, Miyuki Toake, Hiromitsu Takahashi, Takahiro Irie, Hirotaka Momose, Kota Amemiya, Yuki Tsuchiya, Ryoichi Tsukamoto, Hisashi Ro, Kumpei Honjo, Masaya Kawai, Shun Ishiyama, Kazuhiro Sakamoto

{"title":"[A Case of Locally Advanced Colorectal Cancer with Severe Bladder Invasion Successfully Treated with Preoperative Chemotherapy with Anti-EGFR Antibody and Avoiding Total Bladder Resection].","authors":"Jyunta Hayashi, Kiichi Sugimoto, Saki Kochi, Miyuki Toake, Hiromitsu Takahashi, Takahiro Irie, Hirotaka Momose, Kota Amemiya, Yuki Tsuchiya, Ryoichi Tsukamoto, Hisashi Ro, Kumpei Honjo, Masaya Kawai, Shun Ishiyama, Kazuhiro Sakamoto","doi":"","DOIUrl":"","url":null,"abstract":"In recent years, the efficacy of preoperative treatment for locally advanced colorectal cancer has been reported to improve surgical cure rates and decrease postoperative recurrence rates. In this study, we report a case of locally advanced colorectal cancer with severe bladder invasion that responded to preoperative chemotherapy with an anti-EGFR antibody, resulting in the avoidance of total bladder resection. After diverting colostomy to change the bowel route, the patient underwent 5 courses of mFOLFOX6 therapy and 3 courses of mFOLFOX6 + cetuximab therapy to preserve bladder integrity. After confirming tumor shrinkage through imaging, laparoscopic high-level anterior resection and partial bladder resection were performed, allowing for R0 resection and bladder preservation. Approximately 4 years have passed since the resection of the primary tumor, and there has been no recurrence of the primary disease. Therefore, the indications and efficacy of preoperative treatment with molecularly targeted drugs, including anti-EGFR antibody drugs, for locally advanced colorectal cancer should be investigated in a prospective clinical trial.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 4","pages":"307-309"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148017776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Comprehensive Analysis of Spatial and Temporal Tumor Heterogeneity of Immune Checkpoint Molecules in GastricCancer]. [胃癌免疫检查点分子时空异质性综合分析]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-04-01

Kohei Yamashita, Hiroki Tsubakihara, Chihiro Matsumoto, Keisuke Kosumi, Kazuto Harada, Kojiro Eto, Satoshi Ida, Yohei Nagai, Yuji Miyamoto, Masaaki Iwatsuki

{"title":"[Comprehensive Analysis of Spatial and Temporal Tumor Heterogeneity of Immune Checkpoint Molecules in GastricCancer].","authors":"Kohei Yamashita, Hiroki Tsubakihara, Chihiro Matsumoto, Keisuke Kosumi, Kazuto Harada, Kojiro Eto, Satoshi Ida, Yohei Nagai, Yuji Miyamoto, Masaaki Iwatsuki","doi":"","DOIUrl":"","url":null,"abstract":"The introduction of immune checkpoint inhibitors (ICIs) has led to significant advances in the treatment of gastric cancer. Immune-related biomarkers, including PD-L1 expression, are currently used to guide therapeutic decision‒making; however, recent studies have highlighted the complex biological heterogeneity underlying tumor-immune interactions in gastric cancer. Tumors exhibit spatial heterogeneity, with region-specific molecular and immune profiles, as well as temporal heterogeneity, characterized by dynamic changes in immune features in response to treatment and over time. Advances in single-cell analyses and spatial transcriptomics have further demonstrated that immunosuppressive tumor ecosystems can be spatially localized, and that therapeutic interventions themselves may influence the expression dynamics of immune checkpoint molecules. In this review, we focus on immune checkpoint molecules in gastric cancer and summarize current insights into spatial and temporal tumor heterogeneity, discussing their clinical implications and considerations for the interpretation of immunerelated biomarkers.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 4","pages":"249-254"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148017751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[The Current Landscape of Clinical Implementation of Whole Genome Sequencing]. [全基因组测序临床应用的现状]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-04-01

Hiroyuki Fujii, Kuniko Sunami, Takashi Kohno

{"title":"[The Current Landscape of Clinical Implementation of Whole Genome Sequencing].","authors":"Hiroyuki Fujii, Kuniko Sunami, Takashi Kohno","doi":"","DOIUrl":"","url":null,"abstract":"Whole genome sequencing (WGS) interrogates the entire approximately 3-billion-base-pair human genome and uniquely enables integrated capture of multilayered information, including variants in noncoding regions, repeat elements, complex structural variants, viral genomes, the mitochondrial genome, HLA types, and pharmacogenomic markers. Compared with comprehensive genomic profiling (CGP), which targets predefined cancer genes, WGS offers a vastly broader scope but entails substantial challenges in specimen requirements, computational infrastructure, and standardization of variant interpretation. Recent large-scale clinical studies have shown that WGS provides actionable insights that inform therapy selection and prompt diagnosis, and preparations for clinical deployment are advancing in both oncology and rare-disease medicine. Internationally, initiatives such as the UK 100,000 Genomes Project and the Netherlands' WIDE study/OncoAct® have marked key implementation milestones, while in Japan the\"Action Plan for Whole Genome Analysis 2022\"is establishing the framework for translation to practice and patient benefit. This review surveys WGS from technical foundations to clinical utility, global implementation, ongoing efforts and infrastructure in Japan, and remaining challenges. It sets out the case for repositioning WGS from a research tool to a patient-oriented foundational technology and outlines its potential to deliver patient benefit and accelerate drug development.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 4","pages":"237-243"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148017806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Impact of Closed System Drug Transfer Device Architecture on Medical Waste Reduction - A Comparative Analysis of Filter-versus Barrier-Based Designs]. [封闭系统药物转移设备架构对医疗废物减少的影响——基于过滤器和基于屏障设计的比较分析]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-04-01

Yasunari Okuda, Takahiro Saito, Yuki Mikame, Makoto Shinada, Daichi Arai, Erika Kanai, Izumi Tamura, Maaya Hasegawa, Shion Tanio, Saeko Usui, Ayano Katsura, Haruka Niimura, Tomohito Nakazawa, Yasushi Imai

{"title":"[Impact of Closed System Drug Transfer Device Architecture on Medical Waste Reduction - A Comparative Analysis of Filter-versus Barrier-Based Designs].","authors":"Yasunari Okuda, Takahiro Saito, Yuki Mikame, Makoto Shinada, Daichi Arai, Erika Kanai, Izumi Tamura, Maaya Hasegawa, Shion Tanio, Saeko Usui, Ayano Katsura, Haruka Niimura, Tomohito Nakazawa, Yasushi Imai","doi":"","DOIUrl":"","url":null,"abstract":"Closed system drug transfer devices (CSTDs) are recommended to minimize occupational exposure to antineoplastic drugs, yet their bulky components may increase medical waste. To compare waste volume/weight, greenhouse-gas (GHG) emissions, and disposal cost between filter-based and barrier-based CSTDs under real-world workload. A simulated preparation of 93 inpatient/outpatient chemotherapy cases (322 vials, 342 syringes) was performed using 2 filter CSTDs (Chemo-SafeLockTM and Chemfort®) and 1 barrier CSTD (PhaSealTM). Used components were shaken vertically in a 40-L container (2.5 Hz, 60 s) to determine packed volume and weight. Daily differences were extrapolated to the annual hospital activity (93 preparations × 246 days). Costs and GHG reductions were calculated with national disposal parameters. Filter CSTDs reduced waste volume by 27.9% (84.0 ± 2.3 L vs 114.4 L, p<0.01) without significant weight change. Full conversion would save 187 pails (7.5 kL), 1.06 million JPY, and 0.60 t-CO2e annually. Filter CSTDs provides equivalent containment while markedly decreasing waste and environmental impact, supporting their preferential adoption in sustainable oncology practice.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 4","pages":"265-268"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148017683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0